GlassScriptPhysician profile
Naser M Khan
NPI 1437270253
$3,235.09
in general payments reported to CMS, 2019-2025
16 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.16 · 2020: $13.96 · 2021: $329 · 2022: $79.60 · 2023: $390 · 2024: $1,977 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471 · Travel and Lodging: $1,302 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.37 |
| Travel and Lodging | $1,302.18 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,655.15 | 2023-2024 | Apollo Esg Nxt System, Exalt Model D |
| Abbvie INC. | $368.67 | 2019-2025 | |
| Janssen Biotech, INC. | $340.32 | 2021-2025 | Tremfya, Stelara |
| Apollo Endosurgery US INC | $136.26 | 2023 | Overstitch Endoscopic Suturing System |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Janssen Scientific Affairs, LLC | $124.29 | 2023-2025 | Tremfya, Stelara |
| Celltrion USA INC. | $123.09 | 2025 | Vegzelma |
| Capsovision, INC. | $91.47 | 2025 | Capsocam Plus |
| Endogastric Solutions, INC | $79.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.19 | 2021 | |
| Intercept Pharmaceuticals, INC. | $34.28 | 2021 | |
| Braintree Laboratories, INC. | $31.37 | 2021 | |
| Gilead Sciences, INC. | $28.23 | 2021 | |
| Daiichi Sankyo INC. | $23.11 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $13.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naser Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.